TargetMol

Retelliptine

Product Code:
 
TAR-T28521
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28521-5mg5mg£1,251.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28521-50mg50mg£2,464.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28521-100mg100mg£3,283.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Retelliptine, a DNA topoisomerase II inhibitor, is used potentially for the treatment of cancer.
CAS:
72238-02-9
Formula:
C25H32N4O
Molecular Weight:
404.558
Purity:
0.98
SMILES:
CCN(CC)CCCNc1nccc2c(C)c3[nH]c4ccc(OC)cc4c3c(C)c12

References

1. Kattan J, Durand M, Droz JP, Mahjoubi M, Marino JP, Azab M. Phase I study of retelliptine dihydrochloride (SR 95325 B) using a single two-hour intravenous infusion schedule. Am J Clin Oncol. 1994 Jun;17(3):242-5. PubMed PMID: 8192111. 2. Langdon SP, Hendriks HR, Braakhuis BJ, Pratesi G, Berger DP, Fodstad O, Fiebig HH, Boven E. Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study. Ann Oncol. 1994 May;5(5):415-22. PubMed PMID: 8075048. 3. Maulard C, Urien S, Bastian G, Tillement JP. Binding of retelliptine, a new antitumoral agent, to serum proteins and erythrocytes. Biochem Pharmacol. 1990 Aug 15;40(4):895-8. PubMed PMID: 2386553. 4. Ono K, Nakane H, Barre-Sinoussi F, Chermann JC. Differential inhibition by an antitumoral drug 10-[gamma-diethylaminopropylamino]-6-methyl-5H-pyrido[3',4': 4,5]pyrrolo [2,3-G]isoquinoline (BD-40), a pyrido-pyrrolo-isoquinoline derivative, of in vitro DNA synthesis catalyzed by various DNA polymerases. Cancer Lett. 1990 May 15;51(1):59-65. PubMed PMID: 1692511.